Trial Profile
A Multi-center Study to Evaluate the Pharmacokinetics of 21-Desacetyldeflazacort and the Safety of Deflazacort After Oral Administration of Deflazacort Tablets to Children and Adolescent Subjects With Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deflazacort (Primary)
- Indications Duchenne muscular dystrophy
- Focus Pharmacokinetics
- Sponsors Marathon Pharmaceuticals
- 20 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Sep 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.
- 10 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.